Unlocking the potential of pyroptosis in tumor immunotherapy: a new horizon in cancer treatment DOI Creative Commons
Qinan Yin,

Si-Yuan Song,

Yuan Bian

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: June 14, 2024

Background The interaction between pyroptosis—a form of programmed cell death—and tumor immunity represents a burgeoning field interest. Pyroptosis exhibits dual role in cancer: it can both promote development and counteract by activating immune responses that inhibit evasion encourage death. Current immunotherapy strategies, notably CAR-T therapy checkpoint inhibitors (ICIs), alongside the potential certain traditional Chinese medicinal compounds, highlight intricate relationship pyroptosis cancer immunity. As research delves deeper into mechanisms within therapy, its application enhancing emerges as novel avenue. Purpose This review aims to elucidate underlying pyroptosis, impact on biology, advancements research. Methods A comprehensive literature was conducted across PubMed, Embase, CNKI, Wanfang Database from inception study until August 22, 2023. search employed keywords such “pyroptosis”, “cancer”, “tumor”, “mechanism”, “immunity”, “gasdermin”, “ICB”, “CAR-T”, “PD-1”, “PD-L1”, “herbal medicine”, “botanical “Chinese “traditional “immunotherapy”, linked AND/OR, capture latest findings immunotherapy. Results is governed complex mechanism, with Gasdermin family playing pivotal role. While promising for application, pyroptosis’s effect still evolving. Notably, medicine ingredients have been identified inducers, meriting further exploration. Conclusion consolidates current knowledge It reveals beneficial factor immunotherapeutic landscape, suggesting leveraging developing treatment including those involving medicine, forward-looking approach oncology.

Language: Английский

Targeting PI3K signaling in Lung Cancer: advances, challenges and therapeutic opportunities DOI Creative Commons

Bitian Zhang,

Ping‐Chung Leung, William C. Cho

et al.

Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 14, 2025

Abstract Lung cancer remains the leading cause of cancer-related mortality globally, necessitating continual exploration novel therapeutic targets. The phosphoinositide 3-kinase (PI3K) signaling pathway plays a pivotal role in oncogenic processes, including cell growth, survival, metabolism and immune modulation. This comprehensive review delineates distinct roles PI3K subtypes—PI3Kα, PI3Kβ, PI3Kγ PI3Kδ—in lung pathogenesis progression. We evaluate current landscape inhibitors, transitioning from non-selective early-generation compounds to isoform-specific agents, highlighting their clinical efficacy, resistance mechanisms potential combination strategies. Furthermore, intricate interplay between tumor microenvironment is explored, elucidating how modulation can enhance immunotherapeutic responses. Metabolic reprogramming driven by also dissected, revealing vulnerabilities that be therapeutically exploited. Despite promising advancements, challenges such as adverse effects underscore need for personalized medicine approaches development next-generation inhibitors. underscores multifaceted advocates integrated strategies harness its full potential, paving way improved patient outcomes.

Language: Английский

Citations

1
Advances in Materials Science for Precision Melanoma Therapy: Nanotechnology-Enhanced Drug Delivery Systems DOI Creative Commons
Sivakumar S. Moni, Jobran M. Moshi, Sabine Matou‐Nasri

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 296 - 296

Published: Feb. 24, 2025

Melanoma, a highly aggressive form of skin cancer, poses major therapeutic challenge due to its metastatic potential, resistance conventional therapies, and the complexity tumor microenvironment (TME). Materials science nanotechnology advances have led using nanocarriers such as liposomes, dendrimers, polymeric nanoparticles, metallic nanoparticles transformative solutions for precision melanoma therapy. This review summarizes findings from Web Science, PubMed, EMBASE, Scopus, Google Scholar highlights role in overcoming treatment barriers. Nanoparticles facilitate passive active targeting through mechanisms enhanced permeability retention (EPR) effect functionalization with tumor-specific ligands, thereby improving accuracy drug delivery reducing systemic toxicity. Stimuli-responsive systems multi-stage further improve overcome challenges poor penetration resistance. Emerging platforms combine diagnostic imaging delivery, paving way personalized medicine. However, there are still issues scalability, biocompatibility, regulatory compliance. comprehensive potential integrating genetics proteomics, scalable, patient-specific therapies. These interdisciplinary innovations promise redefine provide safer, more effective, accessible treatments. Continued research is essential bridge gap between evidence-based scientific clinical applications.

Language: Английский

Citations

1
Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges DOI Open Access
S. A. Tilakaratne Bandara, Sreejith Raveendran

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 821 - 821

Published: Feb. 27, 2025

Cancer remains a leading global health challenge, placing immense burdens on individuals and healthcare systems. Despite advancements in traditional treatments, significant limitations persist, including treatment resistance, severe side effects, disease recurrence. Immunotherapy has emerged as promising alternative, leveraging the immune system to target eliminate tumour cells. However, challenges such immunotherapy patient response variability, need for improved biomarkers limit its widespread success. This review provides comprehensive analysis of current landscape cancer immunotherapy, highlighting both FDA-approved therapies novel approaches clinical development. It explores checkpoint inhibitors, cell gene therapies, monoclonal antibodies, nanotechnology-driven strategies, offering insights into their mechanisms, efficacy, limitations. By integrating emerging research advancements, this underscores continued innovation optimise overcome existing barriers.

Language: Английский

Citations

1
Microenvironment-based immunotherapy in oral cancer: a comprehensive review DOI

Hassan Mivehchi,

Aisan Eskandari-Yaghbastlo,

Masumeh Ghazanfarpour

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(5)

Published: March 28, 2025

Language: Английский

Citations

1
From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review DOI Creative Commons

Moksada Regmi,

Yingjie Wang, Weihai Liu

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 43(1)

Published: Feb. 12, 2024

Abstract In tumor therapeutics, the transition from conventional cytotoxic drugs to targeted molecular therapies, such as those targeting receptor tyrosine kinases, has been pivotal. Despite this progress, clinical outcomes have remained modest, with glioblastoma patients' median survival stagnating at less than 15 months. This underscores urgent need for more specialized treatment strategies. Our review delves into progression toward immunomodulation in glioma treatment. We dissect critical discoveries immunotherapy, spotlighting instrumental role of tumor-associated macrophages, which account approximately half immune cells microenvironment, and myeloid-derived suppressor cells. The complex interplay between microenvironment explored, revealing novel therapeutic targets. uniqueness our is its exhaustive approach, synthesizing current research elucidate intricate roles various molecules receptors within microenvironment. comprehensive synthesis not only maps landscape but also provides a blueprint refining immunotherapy glioma, signifying paradigm shift leveraging mechanisms improved patient prognosis.

Language: Английский

Citations

7
Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential DOI Creative Commons
Jan Jakub Lica, Bhaskar Pradhan, Kawthar Safi

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(17), P. 4280 - 4280

Published: Sept. 9, 2024

In this review we explore innovative approaches in the treatment of hematologic cancers by combining various therapeutic modalities. We discuss synergistic potential inhibitors targeting different cellular pathways with immunotherapies, molecular therapies, and hormonal therapies. Examples include PI3K proteasome inhibitors, NF-κB immunotherapy checkpoint neddylation therapies tumor microenvironment. Additionally, use small molecules peptide cancer treatment. These multidimensional combinations present promising strategies for enhancing efficacy overcoming resistance mechanisms. However, further clinical research is required to validate their effectiveness safety profiles patients.

Language: Английский

Citations

7
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 DOI Creative Commons
George Lau, Shuntaro Obi, Jian Zhou

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(6), P. 1661 - 1683

Published: Nov. 21, 2024

In Asia–Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation disease progression in those with not eligible resection failed locoregional therapy. recent few years, new targeted therapy immune-checkpoint inhibitors have been registered as systemic address these issues. Notably, forms therapy, either first-line second-line unresectable now available. New data also emerging use prevent retard future, further implementation other immunotherapy expected bring paradigm management carcinoma. insight related immune-related adverse events has allso enabled optimization therapeutic approach patients The purpose this clinical practice guideline provide an up-to-date recommendation based on evidence experience from expert key opinion leaders field Three questions will be addressed, namely: (1) Which should considered therapy? (2) used? (3) How patient planned immune checkpoint-based managed monitored?

Language: Английский

Citations

7
Novel Therapeutic Approaches for Colorectal Cancer Treatment DOI Open Access
Athanasios G. Papavassiliou, Donatella Delle Cave

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(4), P. 2228 - 2228

Published: Feb. 13, 2024

According to GLOBOCAN 2020 data, colorectal cancer (CRC) represents the third most common malignancy and second deadly worldwide [...]

Language: Английский

Citations

6
The role and participation of immune cells in the endometrial tumor microenvironment DOI
Debasish Kumar Dey,

Danielle Krause,

Rajani Rai

et al.

Pharmacology & Therapeutics, Journal Year: 2023, Volume and Issue: 251, P. 108526 - 108526

Published: Sept. 9, 2023

Language: Английский

Citations

13
Mitochondrial regulation in the tumor microenvironment: targeting mitochondria for immunotherapy DOI Creative Commons

Minseo Ahn,

Akhtar Ali,

Jae Ho Seo

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 11, 2024

Mitochondrial regulation plays a crucial role in cancer immunity the tumor microenvironment (TME). Infiltrating immune cells, including T natural killer (NK) and macrophages, undergo mitochondrial metabolic reprogramming to survive harsh conditions of TME enhance their antitumor activity. On other hand, immunosuppressive cells like myeloid-derived suppressor (MDSCs), regulatory (Tregs), mast tumor-associated macrophages (TAMs) rely on maintain function as well. Additionally, facilitates evasion even hijacks mitochondria from function. Recent studies suggest that targeting can synergistically reduce progression, especially when combined with traditional therapies checkpoint inhibitors. Many mitochondrial-targeting drugs are currently clinical trials have potential efficacy immunotherapy. This mini review highlights critical provides lists

Language: Английский

Citations

5